Impact of pH on activity of trimethoprim, fosfomycin, amikacin, colistin and ertapenem in human urine

Pharmacology

Volumn 90, Issue 5-6, 2012, Pages 281-287

  Burian, A ^a   Erdogan, Z ^a   Jandrisits, C ^a   Zeitlinger, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acidification; Alkalinity; Antibiotic; In vitro tests; Urinary tract infection

Indexed keywords

AMIKACIN; COLISTIN; ERTAPENEM; FOSFOMYCIN; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL STRAIN; BROTH DILUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GROWTH CURVE; HUMAN; IN VITRO STUDY; KLEBSIELLA OXYTOCA; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; STAPHYLOCOCCUS AUREUS; URINE ACIDIFICATION; URINE PH;

AMIKACIN; ANTI-BACTERIAL AGENTS; BACTERIA; BETA-LACTAMS; COLISTIN; FOSFOMYCIN; HUMANS; HYDROGEN-ION CONCENTRATION; MICROBIAL SENSITIVITY TESTS; TRIMETHOPRIM; URINE;

EID: 84866926431     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000342423     Document Type: Article

References (22)

1. Carlsson S, Govoni M, Wiklund NP, Weitzberg E, Lundberg JO: In vitro eval uation of a new treatment for urinary tract infections caused by nitrate-reducing bac teria. Antimicrob Agents Chemother 2003; 47:3713-3718. (Pubitemid 37484977)
2. Wagenlehner FM, Hoyme U, Kaase M, Funfstuck R, Naber KG, Schmiemann G: Uncomplicated urinary tract infections. Dtsch Arztebl Int 2011;108:415-423.
3. Head KA: Natural approaches to prevention and treatment of infections of the lower urinary tract. Altern Med Rev 2008;13:227-244.
4. Turan H, Serefhanoglu K, Torun AN, et al: Frequency, risk factors, and responsible pathogenic microorganisms of asymptomatic bacteriuria in patients with type 2 diabetes mellitus. Jpn J Infect Dis 2008;61: 236-238. (Pubitemid 351888602)
5. Reid G: Potential preventive strategies and therapies in urinary tract infection. World J Urol 1999;17:359-363.
6. Barbosa-Cesnik C, Brown MB, Buxton M, Zhang L, DeBusscher J, Foxman B: Cranberry juice fails to prevent recurrent urinary tract infection: results from a randomized placebo-controlled trial. Clin Infect Dis 2011;52:23-30.
7. Carlsson S, Wiklund NP, Engstrand L, Weitzberg E, Lundberg JO: Effects of pH, nitrite, and ascorbic acid on nonenzymatic nitric oxide generation and bacterial growth in urine. Nitric Oxide 2001;5:580-586. (Pubitemid 34001621)
8. Holland NH, West CD: Prevention of recurrent urinary tract infections in girls. Am J Dis Child 1963;105:560-567.
9. Erdogan-Yildirim Z, Burian A, Manafi M, Zeitlinger M: Impact of pH on bacterial growth and activity of recent fluoroquinolones in pooled urine. Res Microbiol 2011;162: 249-252.
10. Wisell KT, Kahlmeter G, Giske CG: Trimethoprim and enterococci in urinary tract infections: new perspectives on an old issue. J Antimicrob Chemother 2008;62:35-40. (Pubitemid 351865871)
11. Drekonja DM, Johnson JR: Urinary tract infections. Prim Care 2008;35:345-67, vii. (Pubitemid 351680112)
12. Falagas ME, Kasiakou SK: Colistin: the revival of polymyxins for the management of multidrug- resistant gram-negative bacterial infections. Clin Infect Dis 2005;40:1333-1341. (Pubitemid 40570245)
13. Auer S, Wojna A, Hell M: Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum beta-lactamase- producing Escherichia coli. Antimicrob Agents Chemother 2010;54: 4006-4008.
14. Butcu M, Akcay SS, Inan AS, Aksaray S, Engin DO, Calisici G: In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics. J Infect Chemother 2011;17:575-578.
15. Kamberi M, Tsutsumi K, Kotegawa T, Nakamura K, Nakano S: Determination of ciprofloxacin in plasma and urine by HPLC with ultraviolet detection. Clin Chem 1998;44: 1251-1255. (Pubitemid 28283063)
16. Santiso R, Tamayo M, Gosalvez J, Bou G, Fernandez Mdel C, Fernandez JL: A rapid in situ procedure for determination of bacterial susceptibility or resistance to antibiotics that inhibit peptidoglycan biosynthesis. BMC Microbiol 2011;11:191.
17. Jana S, Deb JK: Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 2006;70:140-150.
18. Quinlivan EP, McPartlin J, Weir DG, Scott J: Mechanism of the antimicrobial drug trimethoprim revisited. FASEB J 2000;14: 2519- 2524.
19. Rustigian R, Stuart CA: The biochemical and serological relationships of the organisms of the genus Proteus. J Bacteriol 1945;49: 419-436.
20. Ronald A: The etiology of urinary tract infection: traditional and emerging pathogens. Am J Med 2002;113(suppl 1A): 14S-19S. (Pubitemid 34756641)
21. Swaminathan S, Alangaden GJ: Treatment of resistant enterococcal urinary tract infections. Curr Infect Dis Rep 2010;12:455-464.
22. Frimodt-Moller N: Correlation between pharmacokinet ic/pharmacodynamic parameters and efficacy for antibiotics in the treatment of urinary tract infection. Int J Antimicrob Agents 2002;19:546-553. (Pubitemid 34831659)